Acyclovir Drug Market Scope
Acyclovir is an antiviral drug. It helps to treat the herpes virus in the body. This is not cured of the roots but it helps to lessen the symptoms of the infection. It used in the treatment of herpes viruses such as genital herpes, cold sores, shingles, chickenpox, as well as varicella, and cytomegalovirus. As Herpes infection is contagious in nature, it infected by contact with other people. While pregnancy it’s very important to treat herpes, in these cases acyclovir drug is the best option to deal with it.
The market study is being classified, by Application (Hospital and Drug Store) and major geographies with country level break-up.
The global Acyclovir Drug market is highly competitive and consists of some key players. In terms of market share, few of the key players presently dominate the global market. These market players are leveraging on strategic collaborative creativities to intensification their market share and escalation their profitability. Research Analyst at AMA predicts that Germany Players will contribute to the maximum growth of Global Acyclovir Drug market throughout the predicted period.
GSK (United Kingdom), Zydus Pharmaceuticals (United States), Mylan (United States), Bausch Health (Canada), Vectans Pharma (France), Fresenius Kabi (Germany), Aurobindo Pharma (India), Teva Pharmaceutical Industries (Israel), Heritage Pharmaceuticals (United States) and APOTEX (Canada) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Cadila Pharmaceuticals (India), Amneal Pharmaceuticals (United States), Taro Pharmaceutical (United States), Glenmark (India), G&W Laboratories (United States), Yiling Pharmaceutical Ltd. (China) and Alembic Pharmaceuticals (India).
AdvanceMarketAnalytics has segmented the market of Global Acyclovir Drug market by Type, Application and Region.
On the basis of geography, the market of Acyclovir Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
In Feb 2019, Sol-Gel Technologies Ltd. focused on developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company announced the approval from the United States Food and Drug Administration.
In Apr 2019, the Food and Drug Administration (FDA) approved a new drug application for Avaclyr. Acyclovir is the gold standard treatment in herpes virus infection, it provides therapy inform of the ophthalmic dosage form.
- Technology Advancement in Manufacturing Processes
- Increasing Number of Drug Stores in Emerging Countries
- Rising Number of Skin Infection Diseases Especially With Pregnant Women
- Growing Demand for Topical Dermatological Drugs
- Initiatives Government Initiatives to Help Skin Infection Patients
- Rapid Changes in Technology
- Rising Cost of Raw Materials
- Strict Government Regulations
- Increasing Side Effects Such As Nausea, Vomiting, Diarrhoea, General Ill Feeling, Headache
Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Acyclovir Drug Manufacturers, Suppliers and Distributors, Raw Material Suppliers, Government Regulatory and Research Organizations and End-Use Industries
Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase